Celosia Therapeutics Pty Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Celosia Therapeutics Pty Ltd - overview
Established
2022
Location
Sydney, NSW, Australia
Primary Industry
Biotechnology
About
Founded in 2022 and based in New South Wales, Australia, Celosia Therapeutics Pty Ltd is a privately held pre-clinical stage gene therapy firm focused on discovering treatments for neurodegenerative diseases. Lars M. Ittner and Roger Chung are the co-founders of the company. In October 2022, Celosia Therapeutics raised USD 2 million in seed funding from Macquarie University.
The company is developing product pipelines including ALS CTx-1000, ALS CTx-2000, dementia CTx-3000, epilepsy CTx-4000, and tech development CTx-D1000. The firm is working on neurodegenerative diseases such as ALS/MND/LGD, Alzheimer’s disease, fronto-temporal dementia, and Dravet syndrome. The organisation plans to use the October 2022 funding to develop a gene therapy to treat MND.
Current Investors
Macquarie University, Uniseed, UniSuper
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Chiropractic, Orthopedic & Physical Therapy
Website
www.celosiatx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Celosia Therapeutics Pty Ltd - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.